Novavax's ROE % for the quarter that ended in Dec. 2024 was 0.00%. Novavax's PB Ratio for the quarter that ended in Dec. 2024 was N/A.
Novavax's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was N/A.
Novavax ROE % Adjusted to Book Value Historical Data
The historical data trend for Novavax's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Novavax's ROE % Adjusted to Book Value
For the Biotechnology subindustry, Novavax's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novavax's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Novavax's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Novavax's ROE % Adjusted to Book Value falls into.
Novavax ROE % Adjusted to Book Value Calculation
Novavax's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novavax ROE % Adjusted to Book Value Related Terms
Thank you for viewing the detailed overview of Novavax's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NVAX has been successfully added to your 